Available online 10 March 2023, 101822
Author links open overlay panel, AbstractFor decades, aside from prednisone and the occasional use of immune suppressive drugs such as methotrexate, there was little to offer patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). However, there is a great interest in various steroid sparing treatments in both these conditions. This paper aims to provide an overview of our current knowledge of PMR and GCA, examining their similarities and distinctions in terms of clinical presentation, diagnosis, and treatment, with emphasis placed on reviewing recent and ongoing research efforts on emerging treatment. Multiple recent and ongoing clinical trials are demonstrating new therapeutics that will provide benefit and contribute to the evolution of clinical guidelines and standard of care for patients with GCA and/or PMR.
KeywordsGiant cell arteritis
Polymyalgia rheumatica
Treatment
Biologics
Glucocorticoids
Tocilizumab
Emerging therapies
View full text© 2023 Elsevier Ltd. All rights reserved.
留言 (0)